Neumora Therapeutics, Inc. (NMRA : NASDAQ)
Common Stock
$0.43
USD
+0.07 (20.45%)
Last updated: 2026-10-15
Follow NMRA
NMRA
Neumora Therapeutics, Inc.
WealthAwesomePerformance
1 Day
+20.45%
1 Week
-11.00%
1 Month
-48.63%
YTD
-72.09%
Key Statistics
Market Cap
$80.23M
52W High
$3.65
52W Low
$0.32
P/E Ratio
-
50 Day MA
$1.08
200 Day MA
$1.87
Beta
2.98
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/15/2026 | $0.36 | $0.46 | $0.36 | $0.43 | $0.43 | 6,359,197 |
| 10/14/2026 | $0.39 | $0.40 | $0.32 | $0.35 | $0.35 | 2,797,133 |
| 10/13/2026 | $0.43 | $0.44 | $0.37 | $0.37 | $0.37 | 1,495,809 |
| 10/12/2026 | $0.48 | $0.48 | $0.44 | $0.44 | $0.44 | 1,209,406 |
| 10/9/2026 | $0.47 | $0.51 | $0.47 | $0.48 | $0.48 | 789,400 |
| 10/8/2026 | $0.46 | $0.49 | $0.45 | $0.48 | $0.48 | 1,785,832 |
| 10/7/2026 | $0.46 | $0.48 | $0.45 | $0.47 | $0.47 | 2,754,487 |
| 10/6/2026 | $0.53 | $0.54 | $0.47 | $0.47 | $0.47 | 1,214,223 |
| 10/5/2026 | $0.50 | $0.53 | $0.47 | $0.53 | $0.53 | 2,989,234 |
| 10/2/2026 | $0.56 | $0.56 | $0.48 | $0.50 | $0.50 | 2,689,500 |
Analyst Price Targets
Based on 9 analysts covering NMRA · as of Oct 5, 2026
Wall Street analysts forecast NMRA stock price to rise 1338.6% over the next 12 months.
Consensus
Buy4.22 / 5.00
Avg. Target
US$6.14
+1338.6% Upside
Current Price
US$0.43
Last close
Analyst Breakdown (9 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on NMRA's historical volatility
30-Day Vol
116.3%
Annualized
90-Day Vol
93.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$0.36
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$0.40 | US$0.27 – US$0.60 |
| 60 trading days | US$0.38 | US$0.21 – US$0.67 |
| 90 trading days | US$0.36 | US$0.18 – US$0.72 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-206.19M
- Profit Margin
- 0.00%
- ROE (TTM)
- -187.11%
- EPS (Diluted)
- -1.42
- Book Value
- 0.24
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About NMRA.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| KNDI | Kandi Technologies Group Inc | $4.11 | +928.50% |
| ESLA | Estrella Immunopharma Inc. | $0.54 | +68.35% |
| SDST | Stardust Power Inc. | $0.04 | +55.38% |
| XLAB | Exascale Labs Holdings Inc. Class A Common Stock | $1.36 | +49.70% |
| WETO | Webus International Limited Ordinary Shares | $1.22 | +46.88% |
| RITRF | Reitar Logtech Holdings Limited | $0.02 | +40.85% |
| DRMA | Dermata Therapeutics Inc | $0.91 | +37.19% |
| LESLQ | Leslie's, Inc. | $0.03 | +35.75% |